LSP to deploy $600M fund to retain larger stakes in early-stage European biotechs

New fund to target €25-€30M per company, with focus on European therapeutics and med-tech companies

LSP has formally closed its sixth fund at $600 million, the largest ever for a European life sciences fund. The firm joins a growing number of European VCs that have announced record fund-raisings in recent years, signaling increased funding opportunities for innovation coming out of

Read the full 450 word article

How to gain access

Continue reading with a
two-week free trial.